Troutman Sanders Represents Tribute Pharmaceuticals Canada, Inc. in a Merger with Pozen, Inc. Creating New Pharmaceutical Company Aralez Pharmaceuticals Inc.
VIRGINIA BEACH, Va. - Troutman Sanders represented Tribute Pharmaceuticals Canada, Inc. in a merger with Pozen, Inc. in a United States tax inversion transaction resulting in the creation of a new pharmaceutical company Aralez Pharmaceuticals, Inc., a global specialty pharmaceutical company with operations in Canada, Ireland and the United States. The merger was accompanied by an infusion of US$350 million of new capital in the form of equity, debt and a credit line from a number of leading U.S. and foreign pharmaceutical industry investors.
Aralez now trades on NASDAQ under the ticker symbol “ARLZ" and on the Toronto Stock Exchange (“TSX”) under the ticker symbol “ARZ.”
Troutman Sanders corporate and securities lawyers Tom Rose, David Ghegan, Shona Smith, Lisa Raines, Kristen O’Connor and Dan Howell; tax lawyers Mark Goldsmith and Robert Friedman; IP lawyer Heather Ettinger and team; benefits and employment lawyer Jeff Banish and team; lending lawyer Mike Karpen; HSR lawyer Mitch Portnoy; and CFIUS lawyer Megan Rahman served as U.S. legal counsel for Tribute in the deal.
About Troutman Sanders
With a diverse practice mix, workforce and footprint, Troutman Sanders has cultivated its reputation for a higher commitment to client care for over 120 years. Ideally positioned to help clients across sectors realize their business
goals, the firm’s 650 attorneys transact for growth, resolve mission-threatening disputes and navigate complex legal and regulatory challenges. See
troutman.com for more information.